[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"refractory-hodgkin-lymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:refractory-hodgkin-lymphoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,73,104,130,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100594633","phase-2-ctdna-guided-therapy-for-relapsedrefractory-hodgkin-lymphoma-100594633",false,"NCT07021989","ctDNA-Guided Therapy for Relapsed\u002FRefractory Hodgkin Lymphoma","Pembrolizumab and GVD With ctDNA-guided Consolidation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Histologically confirmed classic Hodgkin lymphoma (including nodular sclerosis, lymphocyte-rich, mixed cellularity, and lymphocyte-depleted Hodgkin lymphoma).\n3. Participants must have relapsed or refractory disease after no more than one line of systemic therapy. First line therapy must have included doxorubicin.\n4. At least one site of FDG-avid disease on PET\u002FCT that is ≥ 1.5 cm in diameter for nodal disease or ≥ 1.0 cm in diameter if extranodal disease.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 (Karnofsky ≥ 50%).\n6. Demonstrates adequate organ function as defined below:\n\n   1. Absolute neutrophil count (ANC) ≥ 1.0 X 10\\^9\u002F L (1000\u002Fmicroliter (mcL), growth factors permitted).\n   2. Platelets ≥ 75 X 10\\^9 \u002F L (75,000\u002FmcL, platelet transfusion independent).\n   3. Total bilirubin ≤ 1.5 x institutional upper limit of normal, unless elevated due to Gilbert's syndrome.\n   4. Aspartate aminotransferase (AST) \u002F (SGOT) ≤3 x institutional upper limit of normal.\n   5. Alanine aminotransferase (ALT) \u002F (SGPT) ≤3 x institutional upper limit of normal.\n   6. Creatinine clearance (CrCl, calculated) ≥ 40 mL\u002Fmin\u002F1.73 m\\^2, calculated using the Cockcroft-Gault equation.\n7. For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n8. Individuals with a history of hepatitis C virus (HCV) infection must have been treated with sustained virologic response. For individuals with HCV infection who are currently on treatment, participants are eligible if there is an undetectable HCV viral load.\n9. Human immunodeficiency virus (HIV)-infected individuals on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n10. Individuals with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n11. Females of reproductive potential (defined below) must be willing to undergo a urine or serum pregnancy test (i.e., human chorionic gonadotropin test) within 72 hours before start of trial therapy. A female is considered to not be of reproductive potential (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice), if the participants meet either of the following two criteria: (1) has reached a postmenopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause); or (2) has undergone surgical sterilization (i.e., hysterectomy and\u002For bilateral oophorectomy for removal of uterus and\u002For ovaries). The result of the urine or serum pregnancy test must be negative in order to administer initiate trial therapy. If a urine pregnancy test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the individual must be excluded from participation if the serum pregnancy result is positive. Pregnant individuals are excluded from this study because there is a potential risk for adverse effects in the unborn child secondary to treatment of the study participant with trial therapy.\n12. Ability to understand and willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Participants who previously received a programmed cell death protein 1 (PD-1) inhibitor-based regimen (e.g., nivolumab or pembrolizumab + AVD) and progressed within 6 months of last done of immune checkpoint inhibitor.\n2. Receipt of systemic anti-cancer therapies or radiation within 2 weeks prior to the start of trial therapy or receipt of antibody therapy within 4 weeks prior to the start of trial therapy.\n3. Has participated in a study of an investigational product and received study treatment or used an investigational device within four weeks of the first dose of treatment.\n4. Prior autologous or allogeneic hematopoietic stem cell transplant.\n5. Systemic autoimmune disease requiring continuous immunosuppressive treatment (≥prednisone 10 mg per day or equivalent), with the exception of autoimmune thyroid disease.\n6. Left ventricular ejection fraction (LVEF) \\\u003C50% as assessed by transthoracic echocardiogram or multigated acquisition (MUGA) scan.\n7. Participants whose lifetime cumulative dose of doxorubicin would exceed 450 mg\u002Fm\\^2 after receiving 4 cycles of pembro + GVD are excluded (i.e., \\>330 mg\u002Fm\\^2 at trial entry).\n8. Has known hypersensitivity to pembrolizumab, gemcitabine, vinorelbine, and\u002For liposomal doxorubicin; or any of their excipients.\n9. Has any significant medical condition or comorbidity that could compromise participants safety in the opinion of the treating investigator (e.g., uncontrolled serious infection).\n10. Individuals who are pregnant or breast-feeding\u002Fchest-feeding. Pregnant and breastfeeding individuals are excluded because there is a potential risk for adverse effects in the unborn\u002Fnursing child secondary to treatment of the study participant with trial therapies. Females of reproductive potential must have a negative pregnancy test before initiation of trial therapy, as outlined in inclusion criterion #12. Breast-feeding should be discontinued before initiation of trial therapy.\n11. Individuals with ongoing Grade 2 events that are not clinically stable or ongoing ≥ Grade 3 events (CTCAE v5.0 grading).\n12. Notification from Foresight Diagnostics that the CLARITY LDT baseline specimen has failed sample quality control (QC) and\u002For the baseline ctDNA is not quantifiable. Note: Foresight will only notify sites if the specimen fails quality control (QC) or is not quantifiable. Sites will not receive notification if the specimen passes QC and is quantifiable. For QC failures, a sample re-draw may be considered upon discussion with and approval by the lead University of California, San Francisco (UCSF) Principal Investigator.\n13. Individuals with any condition or social circumstance that, in the opinion of the investigator, would impair the participant's ability to comply with study activities, interfere with participant safety, or study endpoints.","ALL","18 Years",{"count":19,"type":20},38,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This is a single arm, open-label, multicenter, phase II study of pembrolizumab (pembro), gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) in patients with relapsed or refractory classic Hodgkin lymphoma (cHL) with response-adapted consolidation. This study will investigate using circulating tumor DNA (ctDNA) at pre-determined time points using Foresight CLARITY LDT, an ultra-sensitive liquid biopsy platform that detects Minimal residual disease (MRD) in patients with B-cell lymphomas using the phased variant enrichment and sequencing technology (PhasEDq) to determine response to study interventions.",[26,27,28],"Hodgkin Lymphoma, Adult","Refractory Hodgkin Lymphoma","Classic Hodgkin Lymphoma",[30],"circulating tumor DNA","NOT_YET_RECRUITING","2026-06-02",{"date":34,"type":35},"2026-06-04","ACTUAL",{"date":37,"type":20},"2026-07-01",{"date":39,"type":20},"2033-12-31",{"name":41,"class":42},"Michael Spinner, MD","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100460189","phase-1-testing-the-combination-of-nivolumab-and-astx727-for-relapsed-or-refractory-b-cell-lymphoma-100460189","NCT05272384","Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma","A Phase 1 Study of Nivolumab in Combination With ASTX727 in B-cell Lymphoma (NHL or HL) With an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)","Inclusion Criteria:\n\n* Dose Escalation: Histologically confirmed relapsed or refractory B cell lymphoma (non-Hodgkin lymphoma \\[NHL\\] or Hodgkin lymphoma \\[HL\\])\n* Dose Expansion: Patients must have histologically confirmed relapsed or refractory DLBCL or HL\n* Patients with DLBCL must have failed at least first line chemotherapy and must be transplant ineligible (either secondary to performance status or lack of adequate disease control or patient preference). Patients may be relapsed after autologous or allogeneic stem cell transplant (SCT), or after chimeric antigen receptor (CAR)-T cell therapy\n* In dose escalation patients with HL or B cell NHL other than DLBCL must have relapsed after at least 2 lines of therapy and have no other curative options left. HL patients must be brentuximab vedotin refractory or intolerant. In dose expansion, patients with classic HL must have relapsed after at least 2 lines of therapy, and had autologous stem cell transplantation (ASCT), be ineligible for ASCT, or have refused ASCT. Prior treatment with checkpoint inhibitor is allowed\n* Age \\>= 18 years. Because no dosing or adverse event data are currently available on the use of nivolumab in combination with ASTX727 in patients \\\u003C 18 years of age, children are excluded from this study\n* Eastern Cooperative Oncology Group (ECOG)\u002FKarnofsky performance status =\\\u003C 2 (Karnofsky \\>= 70%)\n* Leukocytes \\>= 1,500\u002FmcL (unless documented bone marrow involvement in which case lower values may be allowed)\n* Absolute neutrophil count \\>= 1,000\u002FmcL (unless documented bone marrow involvement in which case lower values may be allowed)\n* Platelets \\>= 75,000\u002FmcL (unless documented bone marrow involvement in which case lower values may be allowed)\n* Total bilirubin =\\\u003C 1.5 x institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \\[SGOT\\])\u002Falanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\\u003C 3 x institutional ULN\n* Serum creatinine =\\\u003C 1.5 x ULN OR creatinine clearance (CrCl) \\>= 50 mL\u002Fmin (if using the Cockcroft-Gault formula)\n* Patients with a requirement for steroid treatment or other immunosuppressive treatment: Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses \\> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial\n* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated\n* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load\n* Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression\n* Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy\n* Patients with a prior malignancy that has completed treatment and or in remission for at least 3 years, or non-melanoma skin cancer or in situ cancer are eligible for this trial. Patients with concurrent malignancy or recent treatment for a concurrent malignancy are not eligible\n* Patients should be New York Heart Association Functional Classification of class 2B or better\n* The effects of nivolumab and ASTX727 on the developing human fetus are unknown. For this reason and because DNMTi agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential (WOCBP) and men must agree to use highly effective contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. WOCBP should use a highly effective contraception method to avoid pregnancy during treatment with ASTX727 and for at least 6 months after the last dose of investigational drug and must agree not to donate eggs (ova, oocytes) for the purpose of reproduction for the same time period. Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of human chorionic gonadotropin \\[HCG\\]) within 24 hours prior to the start of nivolumab. An extension up to 72 hours prior to the start of study treatment is permissible in situations where results cannot be obtained within the standard 24-hour window. Women must not be breastfeeding. Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men who are sexually active with WOCBP will be instructed to adhere to highly-effective contraceptive measures of birth control and not to father a child while receiving treatment and for a period of 3 months after the last dose of investigational product. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile as well as azoospermic men) do not require contraception\n\n  * Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n  * Women \\\u003C 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).\n  * Women ≥ 50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\> 1 year ago, had chemotherapy-induced menopause with last menses \\> 1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).\n\nWOCBP receiving ASTX727 will be instructed to adhere to contraception for a period of 6 months after the last dose of investigational product. Men receiving ASTX727 and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 3 months after the last dose of investigational product. WOCBP receiving nivolumab as a single agent will be instructed to adhere to contraception for a period of 5 months after the last dose. These durations have been calculated using the upper limit of the half-life for nivolumab (25 days) and are based on the protocol requirement that WOCBP use contraception for 5 half-lives plus 30 days Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she (or the participating partner) should inform the treating physician immediately\n\n* Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity who have a legally-authorized representative (LAR) and\u002For family member available will also be eligible\n\nExclusion Criteria:\n\n* Patients who have had chemotherapy or radiotherapy within 4 weeks (2 weeks for Revlimid, 6 weeks for nitrosoureas or mitomycin C) prior to entering the study. Palliative (limited-field) radiation therapy is permitted, if all of the following criteria are met:\n\n  * Repeat imaging demonstrates no new sites of bone metastases\n  * The lesion being considered for palliative radiation is not a target lesion\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> grade 1) with the exception of alopecia\n* Patients who have had prior treatment with anti-PD-1\u002FPD-L1 inhibitors or anti CTLA4 antibodies and were permanently discontinued from further treatment because of an adverse event. All other prior therapies are permissible. Prior checkpoint inhibitor therapy is allowed if there was no discontinuation due to adverse event\n* Patients who are receiving any other investigational agents\n* Patients with known brain metastases or leptomeningeal metastases may be excluded because of poor prognosis and concerns regarding progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to ASTX727 or nivolumab, including severe hypersensitivity reaction to any monoclonal antibody\n* Patients with uncontrolled intercurrent illness\n* Patients with cognitive or other impairment that would prevent compliance with study requirements\n* Pregnant women are excluded from this study because ASTX727 is a DNMTi agent and nivolumab is a PD-L1 inhibitor with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ASTX727 and nivolumab, breastfeeding should be discontinued if the mother is treated with ASTX727 and nivolumab\n* Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded. These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome (GBS), myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease. Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible. Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible\n* Patients who have had evidence of active or acute diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation should be evaluated for the potential need for additional treatment before coming on study",{"count":51,"type":20},32,[53],"PHASE1","This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. ASTX727 consists of the combination of decitabine and cedazuridine. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Giving nivolumab in combination with ASTX727 may shrink and stabilize cancer.",[56,57,58,59,60,27],"Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Hodgkin Lymphoma","Refractory B-Cell Non-Hodgkin Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","RECRUITING","2026-05-12",{"date":64,"type":35},"2026-05-13",{"date":66,"type":35},"2022-11-03",{"date":68,"type":20},"2027-06-28",{"name":70,"class":71},"National Cancer Institute (NCI)","NIH",9,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100553556","phase-1-an-engineered-sirp-fused-to-anti-pd-l1-and-tgf--fusion-protein-hcb301-in-subjects-with-selected-advanced-tumors-100553556","NCT06487624","An Engineered Sirpα Fused to Anti-Pd-L1 And Tgf-β Fusion Protein (HCB301) in Subjects With Selected Advanced Tumors","A Phase 1, Open-label, Multicenter, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HCB301 in Subjects With Advanced Solid Tumors or Relapsed and Refractory cHL","Inclusion Criteria:\n\n1. Able to understand and be willing to sign the ICF.\n2. Male and female subjects of ≥18 years of age.\n3. Histologically\u002Fcytologically confirmed, locally advanced solid tumor:\n\n   subjects confirmed advanced solid tumors who have relapsed or refractory and should have no options for standard or approved therapies known to potentially confer clinical benefit or classical Hodgkin lymphoma, relapsed or refractory to at least 2 prior lines of systemic therapy.\n4. For subjects with advanced solid tumors - must have at least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at baseline.\n5. For subjects with classical Hodgkin lymphoma - must have classical Hodgkin lymphoma that is measurable or assessable for response.\n6. Must have ECOG performance status of 0 to 1 at Screening.\n7. Able to provide tumor tissue samples.\n8. Have a life expectancy of ≥12 weeks.\n\nExclusion Criteria:\n\n1. With known history of hypersensitivity to any components of HCB301.\n2. Known active or untreated CNS metastases and\u002For carcinomatous meningitis.\n3. Have undergone a major surgery or radical radiotherapy within 28 days or palliative radiotherapy within 14 days or have used a radioactive drug within 56 days prior to the first dose of HCB301.\n4. Clinically significant cardiovascular condition.\n5. Any previous treatment-related toxicities which have not recovered to ≤ Grade 1 as evaluated by National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 or baseline, except alopecia and anemia.\n6. With known inherited or acquired bleeding disorder or bleeding diathesis. .\n7. Have RBC transfusion within 4 weeks prior to Screening.\n8. With a previously documented diagnosis of hemolytic anemia or Evans Syndrome in the last 3 months.\n9. Any investigational or approved systemic cancer therapy administered within 21 days or 5 half-lives, whichever is shorter, before the first dose of the study drug.\n10. Active use of vitamin K antagonist anticoagulant like warfarin. Use of low molecular weight heparin and factor Xa inhibitors will be permitted on case by case basis. There will be no restriction for daily aspirin ≤ 100 mg\u002FQD.\n11. Have used herbal medication within 14 days prior to the first dose of HCB301.\n12. Have received any treatment targeting the SIRPα-CD47, PD-L1, or TGF-β pathway.\n13. Have other malignancies requiring treatment within 2 years prior to the first dose of HCB301.\n14. An investigational device used within 28 days prior to the first dose of HCB301.\n15. Positive for hepatitis B, active hepatitis C infections, positive for HIV, or known active or latent tuberculosis.\n16. Known to have a history of alcoholism or drug abuse.",{"count":81,"type":20},50,[53],"The purpose of this study is to find out whether IV injection of HCB301 is an effective treatment for different types of advanced solid tumors and relapsed and refractory classical Hodgkin lymphomas and what side effects (unwanted effects) may occur in subjects aged 18 years old and above.",[85,27],"Advanced Solid Tumor",[87,88,89,90,91,92],"Immunotherapy","CD47","PD-L1","TGF-beta","Tumor","Cancer","2026-04-07",{"date":95,"type":35},"2026-04-13",{"date":97,"type":35},"2025-04-02",{"date":99,"type":20},"2027-05-31",{"name":101,"class":102},"FBD Biologics Limited","INDUSTRY",7,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100553348","phase-2-a-phase-ii-study-of-the-combination-of-pembrolizumab-and-atra-combination-treatment-of-relapsed-hl-and-b-nhl-100553348","NCT06484920","A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL","A Phase II Study of the Combination of Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Relapsed Hodgkin Lymphoma (HL) and B-Non-Hodgkin- Lymphoma (B-NHL)","Inclusion Criteria:\n\n1. ≥ 18 years old at the time of informed consent\n2. Ability to provide written informed consent and HIPAA authorization\n3. Willingness to comply with all study procedures and be available for the duration of the trial\n4. Have a performance status of 0 to 2 on the ECOG Performance Scale.\n5. Life expectancy ≥12 weeks as per investigator discretion\n6. Patients with histologically proven, relapsed or refractory HL or B-NHL as follows:\n\n   1. HL after failure of at least 1 prior line of systemic therapy\n   2. Primary mediastinal large B-cell lymphoma (PMBCL) that is refractory to first-line therapy\n   3. Other B-cell NHLs after failure of at least 2 prior lines of systemic therapy. The eligible types of B-cell NHLs are:\n\n   i. Diffuse large B cell lymphoma ii. Follicular lymphoma iii. Marginal Zone lymphoma iv. Mantle Cell Lymphoma d. Indolent lymphoma are only eligible if they require systemic treatment e. Lymphocyte predominant HL are eligible Note: Formalin-fixed, paraffin embedded archival tumor sample from the primary cancer must be available for testing. If not available or sufficient, patients will be asked to undergo an US or CT guided biopsy prior to study entry to satisfy this eligibility criterion.\n7. Adequate hematologic and end organ function, defined by the following laboratory results obtained within 10 days prior to the first study treatment: Hematological Absolute neutrophil count (ANC) ≥1,500 \u002FmcL Platelets ≥100,000 \u002F mcL Hemoglobin ≥9 g\u002FdL or ≥5.6 mmol\u002FL without transfusion or EPO dependency (within 7 days of assessment) INR and aPTT ≤1.5 x ULN; this applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose. Renal calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) calculated creatinine clearance ≥ 60 mL\u002Fmin Hepatic Serum total bilirubin\n\n   * 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels \\> 1.5 ULN (patients with known Gilbert disease who have bilirubin levels ≤ 3 x ULN may be enrolled). Patients must be able to undergo biliary stenting if required before or, if required, during the trial AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR\n   * 5 X ULN for subjects with liver metastases Albumin \\>2.5 mg\u002FdL\n8. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Note: Female of childbearing potential definition: (ECOG definition) Any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n   1. Has not undergone a hysterectomy or bilateral oophorectomy; or\n   2. Has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n9. Female subjects of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication.\n\n   Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n\n   Refer to section 8.4.1 for more information.\n10. Male subjects of childbearing potential must agree to use an adequate method of contraception of the protocol, starting with the first dose of study therapy through 120 days after the last dose of study therapy. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject. Refer to section 8.4.1 for more information.\n11. Acceptable methods of contraception include IUD, oral contraceptive, subdermal implant, and double barrier (condom with a contraceptive sponge or contraceptive pessary). Micro-dosed progesterone preparations (\"mini-pill\") are an inadequate method of contraception during treatment with ATRA. If patients are taking this pill they should be instructed to stop, and another form of contraceptive should be prescribed instead.\n12. Patients with a history of CAR-T cell therapy are eligible if ≥ 3 months post treatment.\n\nExclusion Criteria:\n\n1. Patients currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.\n2. Known brain metastases and\u002For leptomeningeal disease. Subjects with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.\n3. Significant reduction in ECOG performance status between the screening\u002F baseline visit and within 72 hours prior to commencement of treatment as per trial protocol, as per the Investigator's assessment, defined as a reduction in ECOG score to 3 or 4.\n4. Patients with a diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs) within 7 days prior to the first dose of trial treatment.\n\n   Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n5. Hypersensitivity to pembrolizumab or any of its excipients.\n6. Contraindication to the use of ATRA including but not limited to: patients with a history of hypersensitivity reaction to tretinoin, vesanoid or related compounds ( i.e. acitretin, isotretinoin, vitamin A); , Tetracyclines, Progesterone (low dose), drugs inducing P450 (rifampicin, glucocorticoids, phenobarbital, etc), ketoconazole and drugs inhibiting p450 (cimetidine, erythromycin, cyclosporine, etc); antifibrinolytic agents (e.g. tranexamic acid, aminocaproic acid, aprotinin) and hydroxyurea)\n7. Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.\n8. Prior chemotherapy targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day -1 or who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. Subjects with chronic conditions such as vision changes or prior hearing loss that is not reasonably expected to be exacerbated by the investigational product may be included. Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study. Note: Subjects with Grade 2 adrenal insufficiency or thyroid conditions who are not expected to resolve to baseline, are on a stable dose of medication may be included if it is not reasonably expected to be exacerbated by the investigational product, and asymptomatic whilst on treatment.\n9. History of malignancy in the last 5 years with the exception of prior history of in situ cancer or basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer. Patients with other malignancies are eligible if they were cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years.\n10. Patient has undergone major surgery, other than diagnostic surgery (i.e., surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day -1 of treatment in this study. Note: If subject received major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting therapy.\n11. Known history of, or any evidence of active, non-infectious pneumonitis.\n12. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy.\n13. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.\n14. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n15. Pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.\n16. Patients on micro-dosed progesterone preparations (\"mini-pill\") who are unwilling to receive an alternative form of contraception.\n17. Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.\n18. Known history of Human Immunodeficiency Virus (HIV) (HIV 1\u002F2 antibodies)\n19. Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n20. known history of active TB (Bacillus Tuberculosis).\n21. Receipt of live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.\n22. Patients who receive a COVID shot and\u002For booster within 4 weeks of Cycle 1 Day -1.\n23. Known sensitivity to retinoic acid derivatives.\n24. Patient is taking any prohibited concurrent medication, including Vitamin A supplements, and CYP3A modulators (inducers and inhibitors) and is unwilling to stop use (washout period of 3 days for this protocol) prior to treatment start and during the trial.\n25. History of allogenic stem cell transplant or received a solid organ transplant. Note: If history of transplant is ≥ 5 years, subjects may be deemed eligible at the discretion of the treating physician. Note: Patients with a history of autologous stem cell transplant performed for lymphoma are eligible.",{"count":112,"type":20},24,[23],"This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or refractory Hodgkin Lymphoma or B-Non-Hodgkin-lymphoma.",[116,27,117,118,119],"Relapsed Hodgkin Lymphoma","Relapsed Non-Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma","B-cell Lymphoma","2026-02-07",{"date":122,"type":35},"2026-02-10",{"date":124,"type":35},"2024-11-18",{"date":126,"type":20},"2029-09",{"name":128,"class":42},"Rita Assi",2,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100429402","phase-2-yttrium-90-labeled-anti-cd25-monoclonal-antibody-combined-with-beam-chemotherapy-conditioning-for-the-treatment-of-primary-refractory-or-relapsed-hodgkin-lymphoma-100429402","NCT04871607","Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma","A Phase 2 Trial of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy (aTac-BEAM) Conditioning for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients With Primary Refractory or Relapsed Hodgkin Lymphoma","Inclusion Criteria Informed Consent and Willingness to Participate 1. Documented informed consent of the participant and\u002For legally authorized representative.\n\n\\- Assent, when appropriate, will be obtained per institutional guidelines Age Criteria, Performance status\n\n1. Age: ≥18 years\n2. Karnofsky performance status ≥ 70%\n3. Life expectancy ≥ 6 months Nature of Illness and Illness Related Criteria\n4. Histologically confirmed HL\n5. High risk relapsed or refractory HL disease defined as having any one of the following:\n\n   * B symptoms at relapse\n   * Extranodal disease at relapse\n   * Primary refractory disease'\n   * Relapse \\\u003C 1 year after completion of frontline therapy\n   * Not in CR at the time of transplant\n   * Relapse after receiving PD1 blockade or brentuximab vedotin as initial therapy\n6. Patients will be enrolled after collection of at least 2.0 x 106 CD34 cells\u002Fkg of autologous hematopoietic progenitor cells (HPC-A) by apheresis.\n7. Recovery from non-hematologic toxicities of salvage cytoreductive chemotherapy to ≤ grade 2 (CTCAE v5).\n\n   Clinical Laboratory and Organ Function Criteria (To be performed prior to Day 1 of protocol therapy)\n8. Serum creatinine ≤ 1.5 mg\u002FdL\n9. Creatinine clearance of ≥ 60 mL\u002Fmin per 24 hour urine test\n10. Total bilirubin ≤ 1.5 X ULN (unless has Gilbert's disease)\n11. AST\u002FSGOT ≤1.5 x ULN (except in cases where abnormal LFTs are due to involvement with HL)\n12. ALT\u002FSGPT ≤ 1.5 x ULN (except in cases where abnormal LFTs are due to involvement with HL)\n13. Left ventricular ejection fraction (LVEF) ≥ 50%\n14. FEV1 \\> 65% of predicted measured, or DLCO (diffusion capacity) ≥ 50% of predicted measured (corrected for hemoglobin).\n\n    Contraception\n15. Agreement by females and males of childbearing potential\\* to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least six months after the last dose of protocol therapy.\n\n    * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \\> 1 year (women only).\n\nExclusion Criteria Prior and concomitant therapies\n\n1. Planned BV consolidation after AHCT\n2. Prior high dose chemotherapy with autologous stem cell transplant, or prior allogeneic transplantation.\n3. Significant prior external beam dose-limiting radiation to a critical organ based on review of the prior radiation treatment records by the Radiation Oncology PI.\n4. Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy.\n\n   Other illnesses or conditions\n5. Myelodysplasia or any active malignancy other than HL, or \\\u003C 5 years remission from any other prior malignancy, except non-melanoma skin cancer, localized prostate cancer or localized cervical cancer\n6. Any cytogenetic abnormality in the bone marrow that is known to be associated with or predictive of myelodysplasia is excluded. This includes, but is not limited to, del(5), del(7), del(11).\n7. Lymphocyte-predominant Hodgkin Lymphoma\n8. History of allergic reactions attributed to compounds of similar chemical or biologic composition to 90Y-basiliximab-DOTA.\n9. Persistent marrow involvement (\\>10%) with HL after salvage cytoreductive therapy and before stem cell mobilization.\n10. BM harvest required to reach adequate cell dose for transplant.\n11. Active Hepatitis B or C viral infection or Hepatitis B surface antigen positive\n12. Positive Human Immunodeficiency Virus antibody, patients with undetectable HIV viral load with CD4 ≥ 300 and are on HAART medication are allowed\n13. Patients should not have any uncontrolled illness including ongoing or active infection.\n14. Patients with psychosocial circumstances or illnesses that preclude protocol participation (to be determined by P.I.)\n15. Pregnant women are excluded from this study because 90Y-basiliximab\u002FDOTA is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother 90Y-basiliximab\u002FDOTA, breastfeeding should be discontinued if the mother is treated with 90Y-basiliximab\u002FDOTA.\n16. Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.\n\n    Noncompliance\n17. Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility\u002Flogistics).\n\n    * Eligibility should be confirmed per institutional policies.",{"count":138,"type":20},33,[23],"This phase II trials studies the effects of yttrium-90 labeled anti-CD25 monoclonal antibody combined with BEAM chemotherapy conditioning in treating patients with Hodgkin lymphoma that does not response to treatment (refractory) or has come back (relapsed). Yttrium-90-labeled anti-CD25 is an antibody (proteins made by the immune system to fight infections) that is attached to a radioactive substance and may kill cancer cells and shrink tumors. Chemotherapy drugs, such as carmustine, etoposide, cytarabine, and melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a peripheral blood stem cell transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow.",[58,27],"2025-12-02",{"date":144,"type":35},"2025-12-04",{"date":146,"type":35},"2021-11-02",{"date":148,"type":20},"2029-10-02",{"name":150,"class":42},"City of Hope Medical Center",1,{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":159,"sex":16,"minAge":160,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":21,"phases":164,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":151},"100485006","phase-2-treatment-strategy-for-relapsedrefractory-hodgkin-lymphoma-100485006","NCT05595447","Treatment Strategy for Relapsed\u002FRefractory Hodgkin Lymphoma","Rescue With Brentuximab Plus PD-1 Blockade Followed by Autotransplantation and Consolidation With Brentuximab Plus PD-1 Blockade in Patients With Relapsed\u002FRefractory Hodgkin Lymphoma: Exploratory Single-arm Analysis","Inclusion Criteria:\n\n1. Relapsed\u002Frefractory Hodgkin lymphoma to ABVD with definition of high risk.\n2. Age ≥ 18 years and ≤ 90 years.\n3. Adequate liver function, defined as:\n\n   * Total serum bilirubin ≤ 1.5 x upper limit of normal (ULN)\n   * Serum aspartate aminotransferase (AST) ≤ 3.0 x ULN\n   * Serum alanine aminotransferase (ALT) ≤ 3.0 x ULN\n4. Adequate renal functions, defined as:\n\n   • Serum creatinine ≤ 1.5x ULN or glomerular filtration rate \\> 50ml\u002Fmin.\n5. ECOG performance status ≤ 3\n6. Women of reproductive potential should have a serum pregnancy test or negative urine.\n7. Prior signature of the informed consent.\n\nExclusion Criteria:\n\n1. Voluntary withdrawal from the study.\n2. Develop grade 3 or 4 toxicity according to the INH scale.\n3. Loss of follow-up",true,"15 Years","90 Years",{"count":163,"type":20},20,[23,165],"PHASE3","The choice of the best second-line therapy in patients with high LH R\u002FR risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.\n\nWhat is the progression-free survival and rate of metabolic responses complete in patients with high-risk R\u002FR HL with the treatment strategy: BV+ PD-1 blockade consolidation with Auto-HSCT and maintenance with BV + PD-blockade\n\n1?",[168,27,169],"Hodgkin Lymphoma","Relapsed Hodgkin's Disease, Adult",[171,172,173],"refractory","relapsed","hodgkin lymphoma","2025-03-10",{"date":176,"type":35},"2025-03-12",{"date":178,"type":35},"2022-10-18",{"date":180,"type":20},"2025-10-18",{"name":182,"class":42},"Hospital Regional de Alta Especialidad del Bajio"]